AUTHOR=Ai Ming-Ying , Chen Yan-Zuo , Kuo Chien-Liang , Chang Wei-Lun 

TITLE=A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 11 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1385318

DOI=10.3389/fcvm.2024.1385318

ISSN=2297-055X

ABSTRACT=The objective of this research was to evaluate the risk of major adverse cardiovascular events (MACEs) associated with the use of various proton pump inhibitors (PPIs) in combination with clopidogrel in patients who have undergone percutaneous coronary intervention (PCI).To accomplish this, we analyzed data from randomized controlled trials and retrospective cohort studies sourced from key electronic databases. These studies specifically examined the effects of different PPIs, such as lansoprazole, esomeprazole, omeprazole, rabeprazole, and pantoprazole, when used in conjunction with clopidogrel on MACEs. The primary focus was on the differential impact of these PPIs, while the secondary focus compared gastrointestinal (GI) bleeding events in groups receiving different PPIs with clopidogrel versus a placebo group. This study's protocol was officially registered with INPLASY (INPLAS202420009). We conducted a network meta-analysis involving 16 studies with a total of 145,999 patients. Our findings indicated that Rabeprazole, when combined with clopidogrel, had the lowest increase in MACE risk (effect size: 1.